265
Participants
Start Date
December 31, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
January 31, 2015
Tivozanib
Capsules for oral administration
Bevacizumab
Solution for intravenous infusion
mFOLFOX6
mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Orszagos Onkologiai Intezet, Budapest
Ziekenhuisnetwerk Antwerpen - AZ Middelheim, Antwerp
St George Hospital, Kogarah
Calvary Mater Newcastle, Waratah
Tweed Hospital, Tweed Heads
Imelda VZW, Bonheiden
Cabrini Hospital Malvern, Malvern
Ballarat Health Services, Ballarat
Border Medical Oncology, Wodonga
Klinikum Wels-Grieskirchen GmbH, Wels
Salzburger Landesklinken, Salzburg
Flinders Medical Centre, Bedford Park
Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza, Gyula
Royal Hobart Hospital, Hobart
Fejer Megyei Szent Gyorgy Korhaz, Székesfehérvár
Medizinische Universitat Graz, Graz
AZ Sint-Lucas Brugge, Bruges
AZ Groeninge - Campus Sint-Niklaas, Kortrijk
Petz Aladar Megyei Oktato Korhaz, Győr
NYU Cancer Institute, New York
Fondazione del Piemonte per I'Oncologia IRCC, Candiolo
Centro Oncologico de Galicia, Galicia
IRCCS Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro, Genova
Oncology Hematology of Lehigh Valley, Bethlehem
Istituto Clinico Humanitas, Rozzano (MI)
Associates of Oncology Hematology, P.C., Rockville
Alamance Regional Medical Center, Burlington
Centro Integral Oncologico Clara Campal, Madrid
University of Florida, Davis Cancer Center (VA), Gainesville
Cleveland Clinic Florida, Weston
Hospital Universitario Marques de Valdecilla, Santander
Azienda Ospedaliero- Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna
Tri Country Hematology / Oncology, Canton
Signal Point Clinical Research Center, LLC, Middletown
Investigative Clinical Research of Indiana, LLC, Indianapolis
Horizon Oncology Research, Inc., Lafayette
University of Michigan Health, Ann Arbor
Hospital Universitario Miguel Servet, Zaragoza
Northwestern University, Chicago
Illinios Cancer Care, Peoria
Genesis Cancer Center, Hot Springs
Cancer Care Associates, Tulsa
Mountain Blue Cancer Care Center, Golden
Northern Utah Associates, Ogden
Banner MD Anderson Cancer Research Center, Gilbert
Arizona Clinical Research Center, Tucson
University of California San Diego-Morris Cancer Center, La Jolla
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage
UC Irvine Medical Center, Division of Hematology/Oncology, Orange
Queen's Medical Center, Honolulu
University of Hawaii, Honolulu
Kaiser Foundation Hospitals, Honolulu
Oregon Health and Science University, Portland
Seattle Cancer Care Alliance, Seattle
British Columbia Cancer Agency, Vancouver
QEII Health Science Centre, Halifax
Hopital De La Cite-De-La-Sante, Laval
Hopital Saint-Luc - Pavillon Principal, Montreal
Chuq Centre Hospitalier Universitaire De Quebec, Québec
Masarykuv onkologicky ustav, Brno
Fakultni nemocnice Hradec Kralove, Hradec Králové
Tampereen yliopistollinen sairaala, Tampere
Turun yliopistollinen keskussairaala, Turku
Amphia Ziekenhuis, Breda
Corporacio Sanitaria Parc Tauli, Sabadell
Hospital Mutua de Terrassa, Terrassa
Addenbrooke's Hospital, Cambridge
Western General Hospital, Edinburgh
Beatson West of Scotland Cancer Center, Glasgow
University College Hospital, London
Maidstone Hospital, Maidstone
Christie Hospital, Manchester
Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough
Lead Sponsor
AVEO Pharmaceuticals, Inc.
INDUSTRY